Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Exclusion Criteria

• •Participants who are currently receiving treatment with any anti-programmed cell death-1/programmed death-ligand 1 (anti-PD-1/PD-L1) antibody, either alone or in combination and who are progressing. Participants must have received at least 4 doses of anti-PD-1/PD-L1 before enrolling into the CMP-001-001 study; or
• •Participants who have previously received any anti-PD-1/PD-L1 therapy, alone or in combination and progressed, regardless of the best overall response to prior anti-PD-1/PD-L1 based therapy. Participants must have received at least 4 doses of anti-PD-1/PD-L1 (Inclusion criterion for Part 1 only)
• •Participants must have at least one tumor lesion with a longest diameter of greater than or equal to (\>=)0.5 centimeter (cm) that can be easily palpated or detected by ultrasound to facilitate intratumoral injection of CMP-001 (that is \[i.e.\], tumor in skin, muscle, subcutaneous tissue or accessible lymph node)
• •Participants must have measurable disease by RECIST version 1.1.
• •Capable of understanding and complying with protocol requirements
• •A life expectancy of greater than 24 weeks at Screening
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
• •Most recent laboratory values (within 3 weeks prior to Week 1 Day 1) before study entry meet the following standards:
• •Bone marrow function: neutrophil count \>=1,000/cubic millimeter (mm\^3); platelet count \>=75,000/mm\^3 and hemoglobin concentration \>8.0 grams per deciliter (g/dL).
• •Liver function: total bilirubin less than or equal to (\<=) 1.5 times the upper limit of normal (ULN) ranges of each institution, with the following exception: participants with Gilbert Disease serum bilirubin \> 3\*ULN; and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<=3 times the ULN range of each institution
• +21 more criteria